Mannkind (MNKD) Total Non-Current Liabilities (2012 - 2026)

Mannkind's (MNKD) quarterly Total Non-Current Liabilities came in at $798.5 million in Q1 2026, up 150.64% year-on-year from $318.6 million in Q1 2025, and down 4.73% on a QoQ basis from $838.1 million in Q4 2025.

Mannkind (MNKD) Total Non-Current Liabilities (2012 - 2026) Analysis & Trends

Mannkind (MNKD) has 15 years of Total Non-Current Liabilities data on file, last reported at $798.5 million in Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 150.64% year-over-year to $798.5 million in Q1 2026; TTM through Mar 2026 was $798.5 million, a 150.64% increase from a year earlier, with the FY2025 full-year figure at $838.1 million, up 159.42% from the prior year.
  • Total Non-Current Liabilities for Q1 2026 stood at $798.5 million, down from $838.1 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for MNKD reached as high as $838.1 million in Q4 2025 and fell as low as -$78.3 million in Q4 2023.
  • Historically, Total Non-Current Liabilities has averaged $458.7 million across 5 years, with a median of $526.7 million in 2022.
  • Across the five-year window, Total Non-Current Liabilities slumped 12948.33% in 2023 and soared 512.64% in 2024, its largest moves.
  • Year by year, Total Non-Current Liabilities stood at -$600000.0 in 2022, then slumped by 12948.33% to -$78.3 million in 2023, then surged by 512.64% to $323.1 million in 2024, then surged by 159.42% to $838.1 million in 2025, then slipped by 4.73% to $798.5 million in 2026.
  • Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $798.5 million in Q1 2026, $838.1 million in Q4 2025, and $521.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Mannkind 1.20 Bn 1.07 Bn 82.66 Mn 798.45 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 798.45 Mn
Dec 31, 2025 838.09 Mn
Sep 30, 2025 521.59 Mn
Jun 30, 2025 430.54 Mn
Mar 31, 2025 318.56 Mn
Dec 31, 2024 323.06 Mn
Sep 30, 2024 567.63 Mn
Jun 30, 2024 563.02 Mn
Mar 31, 2024 710.55 Mn
Dec 31, 2023 -78.29 Mn
Sep 30, 2023 560.41 Mn
Jun 30, 2023 323.01 Mn
Mar 31, 2023 552.92 Mn
Dec 31, 2022 -600,000.00
Sep 30, 2022 526.71 Mn
Jun 30, 2022 309.35 Mn
Mar 31, 2022 533.33 Mn
Dec 31, 2021 525.56 Mn
Sep 30, 2021 417.89 Mn
Jun 30, 2021 431.03 Mn